Your browser doesn't support javascript.
loading
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.
Fisk, Marie; Althage, Magnus; Moosmang, Sven; Greasley, Peter J; Cope, Andrew P; Jayne, David Rw; Galloway, James; Hall, Frances; Wilkinson, Ian B; Ambery, Philip; Cheriyan, Joseph.
Afiliación
  • Fisk M; Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Electronic address: mf503@medschl.cam.ac.uk.
  • Althage M; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Moosmang S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Greasley PJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Cope AP; King's College London, Strand, London, WC2R 2LS, UK.
  • Jayne DR; Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
  • Galloway J; King's College London, Strand, London, WC2R 2LS, UK.
  • Hall F; Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
  • Wilkinson IB; Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
  • Ambery P; Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Cheriyan J; Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Pulm Pharmacol Ther ; 69: 102035, 2021 08.
Article en En | MEDLINE | ID: mdl-33933611
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antagonistas de los Receptores de Endotelina / COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Pulm Pharmacol Ther Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antagonistas de los Receptores de Endotelina / COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Pulm Pharmacol Ther Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido